Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGNNASDAQ:DHAINASDAQ:NMTCNASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$2.24+1.1%$2.85$2.00▼$6.75$25.60M1.3211,141 shs5,443 shsDHAIDIH Holding US$0.17+3.6%$0.29$0.12▼$3.67$8.14M-0.17255,892 shs307,946 shsNMTCNeuroOne Medical Technologies$0.65+8.0%$0.83$0.40▼$1.39$30.90M0.61174,339 shs317,463 shsPYPDPolyPid$2.63-1.3%$2.78$2.30▼$5.09$26.76M1.2814,069 shs11,188 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies+10.50%-8.68%-21.07%-41.38%-59.15%DHAIDIH Holding US+0.06%+10.15%-34.99%-84.03%-87.51%NMTCNeuroOne Medical Technologies+2.99%+4.05%-35.45%-49.50%-47.97%PYPDPolyPid-2.92%-2.96%-5.00%-17.90%-41.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLGNCollPlant Biotechnologies1.8138 of 5 stars3.73.00.00.00.00.01.3DHAIDIH Holding US0.9932 of 5 stars0.05.00.00.02.01.70.0NMTCNeuroOne Medical Technologies0.6137 of 5 stars0.03.00.00.02.41.70.0PYPDPolyPid2.4507 of 5 stars3.65.00.00.01.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.33Buy$12.50459.28% UpsideDHAIDIH Holding US 0.00N/AN/AN/ANMTCNeuroOne Medical Technologies 0.00N/AN/AN/APYPDPolyPid 3.25Buy$11.33331.58% UpsideCurrent Analyst Ratings BreakdownLatest DHAI, PYPD, CLGN, and NMTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/27/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/12/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/4/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.001/28/2025PYPDPolyPidRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/28/2025PYPDPolyPidRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$515K49.71N/AN/A$2.47 per share0.90DHAIDIH Holding US$64.47M0.13N/AN/A($0.80) per share-0.22NMTCNeuroOne Medical Technologies$5.75M5.37N/AN/A$0.10 per share6.52PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$7.02M-$1.46N/AN/AN/A-2,680.00%-77.05%-61.43%5/27/2025 (Estimated)DHAIDIH Holding US-$8.44M-$0.30N/A∞N/A-13.59%-5.07%-25.97%N/ANMTCNeuroOne Medical Technologies-$12.32M-$0.26N/A∞N/A-82.17%-270.70%-129.70%5/13/2025 (Estimated)PYPDPolyPid-$29.02M-$4.97N/A∞N/AN/A-624.10%-129.28%5/6/2025 (Estimated)Latest DHAI, PYPD, CLGN, and NMTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PYPDPolyPid-$0.74N/AN/AN/AN/AN/A3/26/2025Q4 2024CLGNCollPlant Biotechnologies-$0.42-$0.34+$0.08-$0.34$0.36 million$0.17 million2/14/2025Q3 2025DHAIDIH Holding USN/A-$0.11N/A-$0.11N/A$15.09 million2/12/2025Q1 2025NMTCNeuroOne Medical TechnologiesN/A$0.06N/A$0.06N/AN/A2/12/2025Q4 2024PYPDPolyPid-$0.90-$1.13-$0.23-$1.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/ADHAIDIH Holding USN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A5.385.23DHAIDIH Holding USN/A0.510.41NMTCNeuroOne Medical TechnologiesN/A3.642.41PYPDPolyPid0.081.311.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%DHAIDIH Holding US27.76%NMTCNeuroOne Medical Technologies16.07%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%DHAIDIH Holding US49.58%NMTCNeuroOne Medical Technologies8.90%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7011.46 million10.36 millionOptionableDHAIDIH Holding USN/A47.34 million20.44 millionN/ANMTCNeuroOne Medical Technologies2047.39 million28.12 millionOptionablePYPDPolyPid8010.19 million7.67 millionNo DataDHAI, PYPD, CLGN, and NMTC HeadlinesRecent News About These CompaniesPolyPid to Participate in The Citizens Life Sciences ConferenceApril 22 at 7:00 AM | globenewswire.comPolyPid Ltd. (NASDAQ:PYPD) Short Interest Down 25.9% in MarchApril 19, 2025 | americanbankingnews.comQ1 Earnings Estimate for PolyPid Issued By HC WainwrightApril 18, 2025 | americanbankingnews.comPolyPid management to meet with OppenheimerApril 17, 2025 | markets.businessinsider.comWhat is HC Wainwright's Estimate for PolyPid Q1 Earnings?April 16, 2025 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for PolyPid (NASDAQ:PYPD)April 16, 2025 | americanbankingnews.comBarclays Reaffirms Their Hold Rating on PolyPid (PYPD)March 25, 2025 | markets.businessinsider.comPolyPid completes enrollment in SHIELD II Phase 3 trial for D-PLEX100March 12, 2025 | markets.businessinsider.comCraig-Hallum Remains a Buy on PolyPid (PYPD)March 12, 2025 | markets.businessinsider.comPolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection PreventionMarch 11, 2025 | tipranks.comPolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsMarch 11, 2025 | globenewswire.comPolyPid to Participate in the 37th Annual ROTH ConferenceMarch 3, 2025 | globenewswire.comPolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D CostsFebruary 13, 2025 | finance.yahoo.comPolyPid targets SHIELD II trial completion with top-line results in Q2 2025February 12, 2025 | msn.comPolyPid (PYPD) Gets a Buy from JMP SecuritiesFebruary 12, 2025 | markets.businessinsider.comPolyPid Ltd. (PYPD) Q4 2024 Earnings Call TranscriptFebruary 12, 2025 | seekingalpha.comPolyPid Updates: New Board Appointment and SHIELD II Trial ProgressFebruary 12, 2025 | tipranks.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsFebruary 12, 2025 | globenewswire.comCraig-Hallum Sticks to Its Buy Rating for PolyPid (PYPD)February 10, 2025 | markets.businessinsider.comPolyPid Ltd. to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 30, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDHAI, PYPD, CLGN, and NMTC Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$2.24 +0.03 (+1.13%) Closing price 03:25 PM EasternExtended Trading$2.24 +0.01 (+0.45%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.DIH Holding US NASDAQ:DHAI$0.17 +0.01 (+3.55%) Closing price 04:00 PM EasternExtended Trading$0.17 0.00 (-2.33%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.NeuroOne Medical Technologies NASDAQ:NMTC$0.65 +0.05 (+8.04%) Closing price 04:00 PM EasternExtended Trading$0.66 +0.01 (+0.92%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.PolyPid NASDAQ:PYPD$2.66 0.00 (-0.04%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
